Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/5996
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHumeniuk, R.-
dc.contributor.authorOng, J.-
dc.contributor.authorKerr, D.-
dc.contributor.authorWhite, J.-
dc.date.issued1995-
dc.identifier.citationGeneral pharmacology, 1995; 26(2):417-424-
dc.identifier.issn0306-3623-
dc.identifier.urihttp://hdl.handle.net/2440/5996-
dc.description.abstract1. While GABAB antagonists have been examined in vitro, very few have been tested in vivo. A range of GABAB antagonists were tested against baclofen-induced muscle relaxation and hypothermia. 2. The GABAB antagonists exhibited a range of in vivo activity profiles. 3. CGP 35348 showed clear antagonist effects, while BPBA and 4-ABPA appeared to have agonist properties. 4. Phaclofen, 2-hydroxysaclofen, 3-APPA and 9G seemed to have little effect in this system at the doses tested. 5. Differences between in vivo and in vitro activity could be explained by differences in blood-brain barrier permeability, or possible differences in affinities for the sub-classes of GABAB receptors.-
dc.description.statementofresponsibilityRachel E. Humeniuk, Jennifer Ong, David I.B. Kerr and Jason M. White-
dc.language.isoen-
dc.publisherPergamon-
dc.rightsCopyright © 2009 Elsevier B.V.-
dc.subjectGABAB receptor-
dc.subjectphaclofen-
dc.subject2-hydroxysaclofen-
dc.subjectCEP 35348-
dc.subjectBPBA-
dc.subject4-ABPA-
dc.subject3-APPA-
dc.subject9G-
dc.titleCharacterisation of GABAB ligands in vivo-
dc.typeJournal article-
dc.identifier.doi10.1016/0306-3623(94)00175-M-
pubs.publication-statusPublished-
dc.identifier.orcidOng, J. [0000-0002-0958-460X]-
Appears in Collections:Anaesthesia and Intensive Care publications
Aurora harvest 5

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.